FRMM · FORUM MARKETS Inc · Insider Trading

The transaction reported represents the forfeiture of shares to the Issuer, valued based on the closing price of the stock on the vesting date, to satisfy the Reporting Person's tax withholding obligations arising from the vesting and settlement of restricted stock units originally granted on April 2, 2026, and does not represent a discretionary sale by the Reporting Person. The shares were officially issued on August 14, 2026.

The transaction reported represents the forfeiture of shares to the Issuer, valued based on the closing price of the stock on the vesting date, to satisfy the Reporting Person's tax withholding obligations arising from the vesting and settlement of restricted stock units originally granted on April 2, 2026, and does not represent a discretionary sale by the Reporting Person. The shares were officially issued on August 14, 2026.

The reporting person, as sole shareholder of Cyber Citadel, may be deemed to beneficially own the securities owned directly by Cyber Citadel.

The reporting person, as sole shareholder of Cyber Citadel, may be deemed to beneficially own the securities owned directly by Cyber Citadel.

The reporting person, as sole shareholder of Cyber Citadel, may be deemed to beneficially own the securities owned directly by Cyber Citadel.

The reporting person, as sole shareholder of Cyber Citadel, may be deemed to beneficially own the securities owned directly by Cyber Citadel.

The reporting person, as sole shareholder of Cyber Citadel, may be deemed to beneficially own the securities owned directly by Cyber Citadel.

Consists of (i) 41,918 shares of Common Stock underlying restricted stock units ("RSUs") that will vest in full on the date of the Company's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service through such date, and (ii) 200,000 shares of Common Stock underlying RSUs, half of which will vest on the date of the Company's 2026 Annual Meeting of Stockholders and the other half of which will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through each such date.

Consists of (i) 3,562 shares of Common Stock underlying restricted stock units ("RSUs") that will vest in full on the date of the Company's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service through such date, and (ii) 200,000 shares of Common Stock underlying RSUs, half of which will vest on the date of the Company's 2026 Annual Meeting of Stockholders and the other half of which will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through each such date.

Consists of (i) 3,562 shares of Common Stock underlying restricted stock units ("RSUs") that will vest in full on the date of the Company's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service through such date, and (ii) 200,000 shares of Common Stock underlying RSUs, half of which will vest on the date of the Company's 2026 Annual Meeting of Stockholders and the other half of which will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through each such date.

Consists of (i) 163,636 shares of Common Stock underlying performance-based restricted stock units ("PSUs") and (ii) 109,091 shares of Common Stock underlying restricted stock units ("RSUs"). Each PSU and RSU represents a contingent right to receive one share of Common Stock. The PSUs consist of three equal tranches, each of which vests on the later of the date that (a) a specified Issuer stock price performance target is met within five years after the grant date and (b) a specified date, subject to the Reporting Person's continued employment through such later date. The RSUs will vest in one-third installments on August 1 of each of 2026, 2027 and 2028, subject to the Reporting Person's continued employment through each such date.

Consists of (i) 41,918 shares of Common Stock underlying restricted stock units ("RSUs") that will vest in full on the date of the Company's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service through such date, and (ii) 200,000 shares of Common Stock underlying RSUs, half of which will vest on the date of the Company's 2026 Annual Meeting of Stockholders and the other half of which will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through each such date.

Consists of (i) 1,130,987 shares of Common Stock underlying performance-based restricted stock units ("PSUs") and (ii) 753,992 shares of Common Stock underlying restricted stock units ("RSUs"). Each PSU and RSU represents a contingent right to receive one share of Common Stock. The PSUs consist of three equal tranches, each of which vests on the later of the date that (a) a specified Issuer stock price performance target is met within five years after the grant date and (b) a specified date, subject to the Reporting Person's continued employment through such later date. The RSUs will vest in one-third installments on August 1 of each of 2026, 2027 and 2028, subject to the Reporting Person's continued employment through each such date.

Consists of (i) 41,918 shares of Common Stock underlying restricted stock units ("RSUs") that will vest in full on the date of the Company's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service through such date, and (ii) 200,000 shares of Common Stock underlying RSUs, half of which will vest on the date of the Company's 2026 Annual Meeting of Stockholders and the other half of which will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through each such date.

Consists of (i) 41,918 shares of Common Stock underlying restricted stock units ("RSUs") that will vest in full on the date of the Company's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service through such date, and (ii) 200,000 shares of Common Stock underlying RSUs, half of which will vest on the date of the Company's 2026 Annual Meeting of Stockholders and the other half of which will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through each such date.

On February 18, 2026, LCCA Holdings, LLC and the Issuer entered into a Stock Surrender Agreement, whereby LCCA Holdings, LLC surrendered 16,178 shares of common stock to the Issuer for cancellation. LCCA Holdings, LLC surrendered these shares for tax planning purposes and did not receive any consideration from the Issuer in connection with such surrender. The Issuer's Board of Directors approved the Stock Surrender Agreement and the accompanying transactions.

The Reporting Person is the manager of LCCA Holdings, LLC. Mr. Smith disclaims beneficial ownership of the shares of common stock owned directly by LCCA Holdings, LLC, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

On December 1, 2025, the Reporting Person gifted 16,718 shares of common stock to LCCA Holdings, LLC, which is managed by the Reporting Person for the benefit of the Reporting Person's family, for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

The Reporting Person is the manager of LCCA Holdings, LLC. Mr. Smith disclaims beneficial ownership of the shares of common stock owned directly by LCCA Holdings, LLC, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

On December 1, 2025, the Reporting Person gifted 16,718 shares of common stock to LCCA Holdings, LLC, which is managed by the Reporting Person for the benefit of the Reporting Person's family, for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

On November 14, 2025, the Reporting Person gifted 267,137 shares of common stock to LCCA LLC, which is managed by the Reporting Person for the benefit of the Reporting Person's family, for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

The Reporting Person is the manager of LCCA LLC. Mr. Smith disclaims beneficial ownership of the shares of common stock owned directly by LCCA LLC, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

On November 14, 2025, the Reporting Person gifted 149,020 shares of common stock to Verulam LLC, which is managed by the Reporting Person for the benefit of the Reporting Person's family, for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

On November 14, 2025, the Reporting Person gifted 149,020 shares of common stock to Verulam LLC, which is managed by the Reporting Person for the benefit of the Reporting Person's family, for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

The Reporting Person is the manager of Verulam LLC. Mr. Suckling disclaims beneficial ownership of the shares of common stock owned directly by Verulam LLC, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

On November 14, 2025, the Reporting Person gifted 182,742 shares of common stock to Bell Flowers, LLC, which is managed by the Reporting Person for the benefit of the Reporting Person's family, for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

On November 14, 2025, the Reporting Person gifted (a) 40,865 shares of common stock to an externally managed donor advised fund for estate planning purposes; and (b) 370,000 shares of common stock to Pelagic Capital Advisors LLC, which entity he serves as managing partner and founder of (see Footnote 8) for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

The Reporting Person is the managing partner and founder of Pelagic Capital Advisors LLC ("Pelagic"), and therefore may be deemed to beneficially own the securities held by Pelagic. Mr. Rudisill disclaims beneficial ownership of the shares of common stock owned directly by Pelagic, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

On November 14, 2025, the Reporting Person gifted (a) 40,865 shares of common stock to an externally managed donor advised fund for estate planning purposes; and (b) 370,000 shares of common stock to Pelagic Capital Advisors LLC, which entity he serves as managing partner and founder of (see Footnote 8) for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

On November 14, 2025, the Reporting Person gifted 267,137 shares of common stock to LCCA LLC, which is managed by the Reporting Person for the benefit of the Reporting Person's family, for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

On November 14, 2025, the Reporting Person gifted 182,742 shares of common stock to Bell Flowers, LLC, which is managed by the Reporting Person for the benefit of the Reporting Person's family, for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

The Reporting Person is the manager of Bell Flowers, LLC. Ms. Heter disclaims beneficial ownership of the shares of common stock owned directly by Bell Flowers, LLC, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

On November 14, 2025, the Reporting Person transferred 218,456 shares of common stock to New Island Advisors LLC, which is managed by the Reporting Person for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

The Reporting Person is the founder and managing partner of New Island Advisors LLC, and therefore deemed to beneficially own the securities held by such entity. Mr. New disclaims beneficial ownership of the securities owned directly by New Island Advisors LLC, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

On November 14, 2025, the Reporting Person transferred 218,456 shares of common stock to New Island Advisors LLC, which is managed by the Reporting Person for estate planning purposes - There was no change in the beneficial ownership of the gifted shares in connection with such transaction.

54,656 shares vested on the grant date and 54,656 shares vest on January 2, 2026.

Issued in consideration for services rendered and agreed to be rendered to the Issuer as Chief Financial Officer of the Issuer.

443,750 shares vested on the grant date and 443,750 shares vest on January 2, 2026.

Issued in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer.

A total of 176,613 shares of common stock awarded to the Reporting Person by the Issuer were withheld by the Issuer to satisfy tax withholding obligations in connection with the award of an aggregate of 443,750 fully-vested shares of common stock to the Reporting Person on November 12, 2025 (see Footnote 1).

324,874 shares vested on the grant date and 324,874 shares vest on January 2, 2026.

Issued in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer.

A total of 271,635 shares of common stock awarded to the Reporting Person by the Issuer were withheld by the Issuer to satisfy tax withholding obligations in connection with the award of an aggregate of 682,500 fully-vested shares of common stock to the Reporting Person on November 12, 2025 (see Footnote 1).

682,500 shares vested on the grant date and 682,500 shares vest on January 2, 2026.

Issued in consideration for services rendered and agreed to be rendered to the Issuer as Chief Executive Officer and director of the Issuer.

A total of 23,447 shares of common stock awarded to the Reporting Person by the Issuer were withheld by the Issuer to satisfy tax withholding obligations in connection with the award of an aggregate of 54,656 fully-vested shares of common stock to the Reporting Person on November 12, 2025 (see Footnote 1).

476,250 shares vested on the grant date and 476,250 shares vest on January 2, 2026.

Issued in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer.

324,874 shares vested on the grant date and 324,874 shares vest on January 2, 2026.

Issued in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer.

A total of 142,132 shares of common stock awarded to the Reporting Person by the Issuer were withheld by the Issuer to satisfy tax withholding obligations in connection with the award of an aggregate of 324,874 fully-vested shares of common stock to the Reporting Person on November 12, 2025 (see Footnote 1).

A total of 257,794 shares of common stock awarded to the Reporting Person by the Issuer were withheld by the Issuer to satisfy tax withholding obligations in connection with the award of an aggregate of 476,250 fully-vested shares of common stock to the Reporting Person on November 12, 2025 (see Footnote 1).

A total of 175,854 shares of common stock awarded to the Reporting Person by the Issuer were withheld by the Issuer to satisfy tax withholding obligations in connection with the award of an aggregate of 324,874 fully-vested shares of common stock to the Reporting Person on November 12, 2025 (see Footnote 1).

On August 21, 2025, the Voting Agreement discussed in footnote (5) below expired pursuant to its terms.

On February 21, 2025, the Issuer, the Reporting Person and Dr. Marlene Krauss, entered into a Voting Agreement, whereby Dr. Krauss agreed to vote a total of 200,000 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to August 21, 2025. In order to enforce the terms of the Voting Agreement, Dr. Krauss provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 200,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.

Issued in consideration for advisory and consulting services agreed to be rendered by PCAO.

These warrants are currently exercisable, subject to a blocker provision that prevents PCAO (defined below) from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock following such exercise, which percentage may be increased to up to 19.99% with at least 61 days prior written notice to the Issuer.

The warrants have no expiration date.

The Reporting Person is the managing partner of PCAO LLC ("PCAO"), and therefore may be deemed to beneficially own the securities held by such entity. Mr. Rudisill disclaims beneficial ownership of the shares of securities owned directly by PCAO, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a director of the Issuer.

The options were granted under the 2025 Second Supplemental Option Plan of the Issuer. The options vested immediately, but are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan is received. If stockholder approval is not received prior to August 8, 2026, the options will be cancelled.

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a director of the Issuer.

The options were granted under the 2025 Second Supplemental Option Plan of the Issuer. The options vested immediately, but are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan is received. If stockholder approval is not received prior to August 8, 2026, the options will be cancelled.

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as an officer of the Issuer.

The options were granted under the 2025 Second Supplemental Option Plan of the Issuer. The options vested immediately, but are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan is received. If stockholder approval is not received prior to August 8, 2026, the options will be cancelled.

On February 5, 2025, the Issuer, the Reporting Person and Dr. James Woody, entered into a Voting Agreement, whereby Dr. Woody agreed to vote a total of 43,166 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to February 5, 2026, the date after August 5, 2025, that Dr. Woody has sold all of the shares or the date that the Issuer terminates the Voting Agreement. In order to enforce the terms of the Voting Agreement, Dr. Woody provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 43,166 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a director of the Issuer.

The options were granted under the 2025 Supplemental Option Plan of the Issuer. The options vested immediately, but were not exercisable until or unless the closing of the transactions contemplated by the July 29, 2025, Securities Purchase Agreement between the Issuer and the purchasers set forth therein occurred, which closing date was August 4, 2025. Separately, the options are not exercisable until stockholder approval of the 2025 Plan is received. If stockholder approval is not received prior to July 29, 2026, the options will be cancelled.

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a director of the Issuer.

The options were granted under the 2025 Supplemental Option Plan of the Issuer. The options vested immediately, but were not exercisable until or unless the closing of the transactions contemplated by the July 29, 2025, Securities Purchase Agreement between the Issuer and the purchasers set forth therein occurred, which closing date was August 4, 2025. Separately, the options are not exercisable until stockholder approval of the 2025 Plan is received. If stockholder approval is not received prior to July 29, 2026, the options will be cancelled.

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as an officer of the Issuer.

The options were granted under the 2025 Supplemental Option Plan of the Issuer. The options vested immediately, but were not exercisable until or unless the closing of the transactions contemplated by the July 29, 2025, Securities Purchase Agreement between the Issuer and the purchasers set forth therein occurred, which closing date was August 4, 2025. Separately, the options are not exercisable until stockholder approval of the 2025 Plan is received. If stockholder approval is not received prior to July 29, 2026, the options will be cancelled.

On February 5, 2025, the Issuer, the Reporting Person and Dr. James Woody, entered into a Voting Agreement, whereby Dr. Woody agreed to vote a total of 43,166 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to February 5, 2026, the date after August 5, 2025, that Dr. Woody has sold all of the shares or the date that the Issuer terminates the Voting Agreement. In order to enforce the terms of the Voting Agreement, Dr. Woody provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 43,166 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.

Transfer to a controlled entity, solely for tax planning purposes only. No change in beneficial ownership.

Transfer to a controlled entity, solely for tax planning purposes only. No change in beneficial ownership.

Mr. Jordan owns and controls Blair Jordan Strategy and Finance Consulting Inc. and as such is deemed to beneficially own the securities held by such entity.